Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Konekt Limited (Konekt)

ABN

3

79 009 155 971

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

partly paid

+convertible

amount

1 +Class of +securities issued or to be issued Performance Rights

2 Number of *securities issued or to be issued (if known) or maximum number which may be issued

the

outstanding and due dates for

securities, the conversion price

if

and dates for conversion)

expiry date; if

+securities,

payment;

Principal terms of the +securities Exercise Price: Nil (e.g. if options, exercise price and

193,026

Expiry Date: The Performance Rights will expire if no Rights Vest or 6 months following the date of the Notice of Vesting issued in relation to any Rights.

Issued subject to service and performance vesting conditions from 1 July 2019 to 30 June 2022 (Performance Period).

| 4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? No. 9 Performance Rights are not quoted securities and on on rank equally with ordinary shares. Performance Rights do not confer a right to vote, a right to receive dividends or any other rights of a shareholder. Any ordinary share issued to the holder of a performance right upon vesting will rank equally from the date of allotment with ordinary shares. 9 the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 5 Issue price or consideration (If issued as consideration for the acquisition of assets, clearly identify those assets) 6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h is nelation to the *securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder resolution under rule 7.1A was passed 6c Number of *securities issued without security holder approval under rule 7.1 6d Number of *securities issued without security holder approval under rule 7.1A | | | |
|---|----|---|---|
| 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) 6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h <i>in relation to the *securities the</i> <i>subject of this Appendix 3B</i>, and comply with section 6i 6b The date the security holder resolution under rule 7.1A was passed 6c Number of *securities issued without security holder approval under rule 7.1 6d Number of *securities issued with security holder approval Nil | 4 | all respects from the +issue date with an existing +class of quoted +securities? If the additional +securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or | Performance Rights are not quoted securities and do not rank equally with ordinary shares. Performance Rights do not confer a right to vote, a right to receive dividends or any other rights of a shareholder. Any ordinary share issued to the holder of a performance right upon vesting will rank equally from the date of allotment with |
| 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) 6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h <i>in relation to the *securities the</i> <i>subject of this Appendix 3B</i>, and comply with section 6i 6b The date the security holder resolution under rule 7.1A was passed 6c Number of *securities issued without security holder approval under rule 7.1 6d Number of *securities issued with security holder approval Nil | | | |
| (If issued as consideration for the acquisition of assets, clearly identify those assets) 6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h <i>in relation to the *securities the subject of this Appendix 3B</i>, and comply with section 6i 6b The date the security holder resolution under rule 7.1A was passed 6c Number of *securities issued without security holder approval under rule 7.1 6d Number of *securities issued with security holder approval | 5 | Issue price or consideration | Nil |
| a that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder resolution under rule 7.1A was passed 6c Number of *securities issued without security holder approval under rule 7.1 6d Number of *securities issued with security holder approval | 6 | (If issued as consideration for the acquisition of assets, clearly | |
| resolution under rule 7.1A was passed 6c Number of *securities issued without security holder approval under rule 7.1 6d Number of *securities issued Nil | ба | that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and | Yes |
| without security holder approval under rule 7.1 6d Number of *securities issued with security holder approval | 6b | resolution under rule 7.1A was | 3 October 2019 |
| with security holder approval | 6с | without security holder approval | 193,026 |
| | 6d | with security holder approval | Nil |
| | | | |

- 6e Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
- 6f Number of +securities issued under an exception in rule 7.2
- 6g If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.
- 6h If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- 7 ⁺Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

8 Number and ⁺class of all ⁺securities quoted on ASX (*including* the ⁺securities in section 2 if applicable)

| Number | +Class | | |
|---------------------------------|-----------------|------|----------|
| 105,786,835 Shares on issue. | Fully shares | paid | ordinary |

Nil

Nil

N/A

N/A

Remaining capacity:

LR 7.1 – 14,459,564

LR 7.1A - 10,578,684

3 October 2019

| | | Number | +Class |
|----|---|-------------------------|---------------------------|
| 9 | Number and ⁺ class of all | 960,000 | Unlisted \$0.362 |
| | *securities not quoted on ASX | | Options expiring 29 |
| | (<i>including</i> the ⁺ securities in | | February 2020 at 5pm |
| | section 2 if applicable) | | AEST. |
| | | | |
| | | 2,878,885 | Unlisted Performance |
| | | | Rights issued on 10 |
| | | | October 2017, 16 |
| | | | November 2017, 19 |
| | | | September 2018, 2 |
| | | | November 2018, 13 |
| | | | September 2019 and 3 |
| | | | October 2019 expiring |
| | | | 6 months following the |
| | | | date of the Notice of |
| | | | Vesting issued in |
| | | | relation to any Rights |
| | | | that vest |
| | | | |
| 10 | Dividend policy (in the case of a | N/A. No Dividends p | ayable on Performance |
| | trust, distribution policy) on the | Rights. New shares when | issued on exercise of the |
| | | | |

dividends.

Performance Rights will rank equally for future

Part 2 - Pro rata issue

increased capital (interests)

| 11 | Is security holder approval required? | Not applicable. |
|----|---|-----------------|
| 12 | Is the issue renounceable or non- renounceable? | Not applicable. |
| 13 | Ratio in which the ⁺ securities will be offered | Not applicable. |
| 14 | ⁺ Class of ⁺ securities to which the offer relates | Not applicable. |
| 15 | ⁺ Record date to determine entitlements | Not applicable. |
| 16 | Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? | Not applicable. |
| 17 | Policy for deciding entitlements in relation to fractions | Not applicable. |

| 18 | Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their | Not applicable. |
|----|---|-----------------|
| | entitlements are to be dealt with. Cross reference: rule 7.7. | |
| 19 | Closing date for receipt of acceptances or renunciations | Not applicable. |
| 20 | Names of any underwriters | Not applicable. |
| 21 | Amount of any underwriting fee or commission | Not applicable. |
| 22 | Names of any brokers to the issue | Not applicable. |
| | | |
| 23 | Fee or commission payable to the broker to the issue | Not applicable. |
| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders | Not applicable. |
| 25 | If the issue is contingent on security holders' approval, the date of the meeting | Not applicable. |
| 26 | Date entitlement and acceptance form and offer documents will be sent to persons entitled | Not applicable. |
| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders | Not applicable. |
| 28 | Date rights trading will begin (if applicable) | Not applicable. |
| 29 | Date rights trading will end (if applicable) | Not applicable. |
| | | |
| 30 | How do security holders sell their entitlements <i>in full</i> through a broker? | Not applicable. |

| 31 | How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance? | Not applicable. |
|----|---|-----------------|
| 32 | How do security holders dispose of their entitlements (except by sale through a broker)? | Not applicable. |
| 33 | +Issue date | Not applicable. |
| | | |

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of ⁺securities (*tick one*)
- (a) ⁺Securities described in Part 1
- (b) All other ⁺securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Tick to indicate you are providing the information or

Additional securities forming a new class of securities

| docume | ents | |
|--------|------|---|
| 35 | | If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders |
| 36 | | If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over |
| 37 | | A copy of any trust deed for the additional ⁺ securities |

Entities that have ticked box 34(b)

| 38 | Number of ⁺ securities for which ⁺ quotation is sought | | |
|----|---|--------|--------|
| 39 | ⁺ Class of ⁺ securities for which quotation is sought | | |
| 40 | Do the ⁺ securities rank equally in all respects from the ⁺ issue date with an existing ⁺ class of quoted ⁺ securities? | | |
| | If the additional ⁺securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment | | |
| 41 | Reason for request for quotation now Example: In the case of restricted securities, end of restriction period | | |
| | (if issued upon conversion of another ⁺ security, clearly identify that other ⁺ security) | | |
| | | | |
| 42 | Number and ⁺ class of all | Number | +Class |
| 42 | *securities quoted on ASX (<i>including</i> the *securities in clause 38) | | |
| | | | |
| Ç | Juotation agreement | | |

- ¹ ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Roule

Sign here:

Print name: Reena Minhas (Company secretary)

Date: 3 October 2019

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

| Rule 7.1 – Issues exceeding 15% of capital | | |
|---|--|--|
| Step 1: Calculate "A", the base figure from which the placement capacity is calculated | | |
| <i>Insert</i> number of fully paid ⁺ ordinary securities on issue 12 months before the ⁺ issue date or date of agreement to issue | 105,336,835 | |
| Add the following: | | |
| Number of fully paid ⁺ordinary securities issued in that 12 month period under an exception in rule 7.2 | 250,000 ordinary shares issued on 20 February 2019 following exercise of options (Exception 4) | |
| Number of fully paid ⁺ordinary securities issued in that 12 month period with shareholder approval | 200,000 ordinary shares issued on 1 March 2019 following exercise of options (Exception 4) | |
| Number of partly paid ⁺ordinary securities that became fully paid in that 12 month period | | |
| Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items | | |
| Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period | Nil | |
| " A " | 105,786,835 | |

⁺ See chapter 19 for defined terms.

| Step 2: Calculate 15% of "A" | | |
|---|--|--|
| "B" | 0.15 [Note: this value cannot be changed] | |
| <i>Multiply</i> "A" by 0.15 | 15,868,025 | |
| Step 3: Calculate "C", the amount of that has already been used | of placement capacity under rule 7.1 | |
| <i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued: | | |
| Under an exception in rule 7.2 | 1,408,461 Performance Rights issued on 13 September 2019 | |
| Under rule 7.1A | | |
| With security holder approval under rule 7.1 or rule 7.4 | | |
| Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items | | |
| "C" | 1,408,461 | |
| Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1 | | |
| "A" x 0.15 | 15,868,025 | |
| Note: number must be same as shown in Step 2 | | |
| <i>Subtract</i> "C" Note: number must be same as shown in Step 3 | 1,408,461 | |
| <i>Total</i> ["A" x 0.15] – "C" | 14,459,564 [Note: this is the remaining placement capacity under rule 7.1] | |

⁺ See chapter 19 for defined terms.

Part 2

| Rule 7.1A – Additional placement capacity for eligible entities | | |
|--|------------------------------------|--|
| Step 1: Calculate "A", the base figure from which the placement capacity is calculated | | |
| "A" | 105,786,835 | |
| Note: number must be same as shown in Step 1 of Part 1 | | |
| Step 2: Calculate 10% of "A" | | |
| "D" | 0.10 | |
| | Note: this value cannot be changed | |
| <i>Multiply</i> "A" by 0.10 | 10,578,684 | |
| Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used | | |
| <i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A | Nil | |
| Notes: • This applies to equity securities – not just | | |
| Include here – if applicable – the securities the subject of the Appendix 3B to which this | | |
| form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), | | |
| or for which specific security holder approval has been obtained | | |
| It may be useful to set out issues of securities on different dates as separate line items | | |
| "E" | Nil | |

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A

| "A" x 0.10 | 10,578,684 |
|---|--|
| Note: number must be same as shown in Step 2 | |
| Subtract "E" | Nil |
| Note: number must be same as shown in Step 3 | |
| <i>Total</i> ["A" x 0.10] – "E" | 10,578,684 |
| | Note: this is the remaining placement capacity under rule 7.1A |